Hims & Hers Halts Wegovy Copycat GLP-1 Drug Sales After FDA Scrutiny
Hims & Hers will stop selling its GLP-1 weight-loss drug branded as a Wegovy copycat following regulatory scrutiny, removing the product from its telehealth treatment lineup. Leadership flagged this move as necessary to comply with FDA concerns, delaying the company’s push into subscription weight-loss therapies.
1. Product Discontinuation
Hims & Hers has indefinitely halted its GLP-1 weight-loss treatment branded as a Wegovy copycat after regulators raised compliance questions over its marketing and distribution. The withdrawal follows an internal review to address FDA concerns and aligns with the company’s commitment to regulatory standards.
2. Financial Implications
The decision removes a relatively new revenue stream from Hims & Hers’ direct-to-consumer telehealth segment, potentially curbing projected growth in subscription-based weight-loss services for the current quarter. Investors will be watching for revisions to top-line guidance as the company adjusts its wellness offerings.
3. Strategic Outlook
Hims & Hers has not announced a replacement therapy but indicated plans to reassess its product portfolio and engage with regulators on potential resumption. Longer-term, the company may shift focus to other areas of dermatology and sexual health services to offset the pause in its weight-loss business.